

## Reliance Pharma Fund

RPF

### Sector Fund

Details as on January 31, 2019

### Type of Scheme

An open ended equity scheme investing in pharma sector

### Current Investment Philosophy

The Fund seeks to invest in pharma sector with focus on important segments of the sector viz Domestic Business, International & CRAMS and include deep value as well as high growth pharma businesses. The fund invests across market capitalization within the sector. It may suit investment horizon of around 2-3 years.

### Date of Allotment

June 5, 2004

### Fund Manager

Sailesh Raj Bhan

### Benchmark

S&P BSE Healthcare

### Fund size

Monthly Average: ₹ 2,697.65 Cr

Month End: ₹ 2,720.20 Cr

### NAV as on January 31, 2019

Growth Plan	₹ 151.6706	Direct - Growth Plan	₹ 159.4893
Dividend Plan	₹ 57.2095	Direct - Dividend Plan	₹ 69.3983
Bonus Option	₹ 151.6706	Direct - Bonus Option	₹ 159.4893

Portfolio Turnover (Times) 0.42

### Total Expense Ratio^

Regular/Other than Direct	2.25
Direct	1.23

### Load structure

Entry Load: Nil

Exit Load: 1% if redeemed or switched out on or before completion of 1 year from the date of allotment of units. Nil, thereafter.

**Special Feature:** Reliance Any Time Money Card

Please refer page no. 78 for explanation on symbol: ^ @ and \*\* wherever available

### Portfolio as on January 31, 2019

Company/Issuer	% of Assets
<b>Healthcare Services</b>	
Thyrocare Technologies Limited	4.04
Fortis Healthcare Limited	3.48
Max India Limited	2.14
Narayana Hrudayalaya Limited	1.04
<b>Pharmaceuticals</b>	
Divi's Laboratories Limited*	10.52
Sun Pharmaceutical Industries Limited*	10.43
Aurobindo Pharma Limited*	9.56
Dr. Reddy's Laboratories Limited*	9.50

Company/Issuer	% of Assets
Sanofi India Limited*	6.70
Cipla Limited*	6.66
Syngene International Limited*	6.61
Biocon Limited*	6.44
Abbott India Limited*	5.93
Lupin Limited*	5.15
Alkem Laboratories Limited	4.67
Cadila Healthcare Limited	2.96
Equity Less Than 1% of Corpus	1.92
<b>Cash and Other Receivables</b>	<b>2.24</b>
<b>Grand Total</b>	<b>100.00</b>

\*Top 10 Holdings

For SIP performance refer page 57. For scheme performance refer page 59-66. For Fund manager wise scheme performance refer page 67-70.

### Volatility Measures

Standard Deviation	4.28	Beta	0.80	Sharpe Ratio	-0.06
--------------------	------	------	------	--------------	-------

**Note:** The above measures have been calculated using monthly rolling returns for 36 months period with 6.50% risk free return (FBIL Overnight MIBOR as on 31/01/2019).

### Dividend History

Record Date	Rate (₹/ Unit)	Cum Dividend NAV	Ex-Dividend NAV	Record Date	Rate (₹/ Unit)	Cum Dividend NAV	Ex-Dividend NAV
<b>Dividend Plan</b>				<b>Direct - Dividend Plan</b>			
01-Mar-18	6.00	58.6103	52.6103	01-Mar-18	6.00	69.2904	63.2904
03-Mar-17	6.50	63.6381	57.1381	03-Mar-17	6.50	73.3984	66.8984
04-Mar-16	7.00	71.2321	64.2321	04-Mar-16	7.00	80.4340	73.4340

**Past performance may or may not be sustained in future.** Pursuant to dividend payment, NAV falls to the extent of payout & statutory levy (if applicable). Face Value-₹10.

### Product Label

**This product is suitable for investors who are seeking\*:**

- Long term capital growth
- Investment in equity and equity related securities of pharma & other associated companies

\*Investors should consult their financial advisors if in doubt about whether the product is suitable for them.

